Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Tesla To Hit 550% Growth By 2030, Says Fund Manager David Baron: Elon Musk Is ‘Not Going To Do Anything Stupid To Change The Trajectory’

By Anan Ashraf

January 27, 3:35 AM

Despite a noticeable slump in growth and profit for Tesla Inc. (NASDAQ:TSLA), fund manager David Baron foresees a…

TSLA

Senmiao Technology Announces Signing Of Cooperation Agreement With Sichuan Province New Energy Vehicle Charging Services Provider

By Benzinga Newsdesk

October 27, 9:04 AM

Senmiao Technology Limited ("Senmiao" or the "Company") (NASDAQ:AIHS), a financing and servicing company focusing on the online ride-hailing industry in China as well as an operator of its

AIHS

Par Pacific Announces Management Promotions; Says William Monteleone Appointed President Effective Jan. 1 2023, Says Shawn Flores Promoted To Senior Vice President, Chief Financial Officer

By Michael Horton

December 19, 6:06 PM

Par Pacific Holdings, Inc. (NYSE:PARR) ("Par Pacific" or the "Company") today announced the appointment of William Monteleone as President effective January 1, 2023. In his new role,

PARR